Ascendiant initiated coverage of Allarity (ALLR) with a Buy rating and $9 price target The firm sees large market opportunities for the company’s DRP platform and Stenoparib drug. It believes positive clinical trial data in 2025 and 2026 will be catalysts for the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR: